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Abstract
N-3 Polyunsaturated fatty acids have been shown to have potential beneficial effects for chronic
diseases including cancer, insulin resistance and cardiovascular disease. Eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) in particular have been studied extensively, whereas substantive
evidence for a biological role for the precursor, alpha-linolenic acid (ALA), is lacking. It is not
enough to assume that ALA exerts effects through conversion to EPA and DHA, as the process is
highly inefficient in humans. Thus, clarification of ALA's involvement in health and disease is
essential, as it is the principle n-3 polyunsaturated fatty acid consumed in the North American diet
and intakes of EPA and DHA are typically very low. There is evidence suggesting that ALA, EPA
and DHA have specific and potentially independent effects on chronic disease. Therefore, this
review will assess our current understanding of the differential effects of ALA, EPA and DHA on
cancer, insulin resistance, and cardiovascular disease. Potential mechanisms of action will also be
reviewed. Overall, a better understanding of the individual role for ALA, EPA and DHA is needed
in order to make appropriate dietary recommendations regarding n-3 polyunsaturated fatty acid
consumption.
Introduction
In recent years, there has been increased focus on the role
of specific dietary fatty acids and their effect on health and
disease. N-3 polyunsaturated fatty acids (PUFA) have
demonstrated a wide range of health-related benefits
including improving heart disease related outcomes,
decreasing tumour growth and metastasis, and favourably
modifying insulin sensitivity. Eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) from marine
sources, in particular, have been studied extensively. The
role of their plant-derived counterpart, alpha-linolenic
acid (ALA) is less clear, yet it is the principle dietary n-3
PUFA consumed in the typical Western diet [1]. Therefore,
the intent of this review is to outline the individual bio-
logical effects of ALA, EPA, and DHA, highlighting differ-
ences in their metabolism and utilization. The role of n-3
fatty acids in cancer, insulin resistance and cardiovascular
disease will be reviewed, given the global prevalence of
the diseases in particular and the emerging associated
health benefits of the individual n-3 PUFA. Potential
mechanisms by which they exert their health-related
effects will also be discussed.
Sources and Metabolism
Polyunsaturated fatty acids are hydrocarbon chains with
two or more double bonds situated along the length of the
carbon chain. Depending on the location of the first dou-
ble bond relative to the methyl terminus, they can be clas-
sified as either n-6 or n-3. Linoleic acid (LA; 18:2n-6), the
parent fatty acid of the n-6 PUFA family is an essential
fatty acid and cannot be endogenously synthesized by
mammals. LA is found in vegetable oils, seeds and nuts.
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ALA (18:3n-3), the parent fatty acid of the n-3 PUFA fam-
ily, must be consumed through the diet. ALA is found in
leafy vegetables, walnuts, soybeans, flaxseed, and seed
and vegetable oils. Both LA and ALA can be further metab-
olized to long chain PUFA through a series of desaturation
and elongation steps. LA is metabolized to arachidonic
acid (AA, 20:4n-6), while ALA can be metabolized to EPA;
(20:5n-3) and ultimately DHA (22:6n-3). Alternatively,
AA can be obtained from animal fat sources and EPA and
DHA can be consumed directly from marine sources.
The average per capita intake of DHA plus EPA is approx-
imately 0.1–0.2 g per day in North America and the aver-
age per capita intake of ALA in North America is ~1.4 g
daily [1]. As mentioned, ALA can be endogenously con-
verted to EPA and DHA, however this is not an efficient
process. Assessment of apparent conversion efficiency of
dietary ALA to EPA and DHA is typically done by measur-
ing the net rise in circulating EPA and DHA after increas-
ing ALA intake. Early studies in this area found that while
some moderate net rise in the level of EPA resulted with
higher levels of ALA, no net rise in the level of circulating
DHA occurred [2,3]. For example, feeding 10.7 g/d of ALA
from flaxseed oil for 4 weeks failed to increase low DHA
levels in breast milk of lactating women [4]. Some esti-
mate that only 5–10% and 2–5% of ALA in healthy adults
is converted to EPA and DHA, respectively [5], while oth-
ers suggest that humans convert less than 5% of ALA to
EPA or DHA [6]. The International Society for the Study of
Fatty Acids and Lipids (ISSFAL) recently released an offi-
cial statement on the conversion efficiency of ALA to
DHA. They concluded that the conversion of ALA to DHA
is on the order of 1% in infants, and considerably lower in
adults [7]. Given the demonstrated benefits of DHA on
visual acuity [8,9] and in the developing mammalian
brain [10,11], poor conversion of ALA to DHA is a con-
cern, particularly for vegetarians and for individuals who
do not eat fatty fish.
Given the poor conversion efficiency of ALA to its longer-
chain counterparts, ALA levels in the blood and tissue of
humans approximate dietary intakes. Since n-3 PUFA in a
typical North American diet is comprised mainly of ALA,
it is pertinent to elucidate the specific effects this fatty
acid. EPA and DHA intake is also low in some European
countries as reviewed [12] and in India [13], making ALA
the principle n-3 PUFA consumed in these regions. The
prevalence of CVD [14], IR [15], and some types of can-
cers [16] in these countries is elevated, in contrast to coun-
tries with high fatty fish intake like Japan [17]. If
conversion efficiency is the main criteria, then the epide-
miological evidence above would suggest that ALA may
not confer the same health benefits as its longer chain
counter-parts, EPA and DHA.
Metabolic Products of n-3 PUFA
Both ALA and LA are converted to their respective long
chain metabolites by the same set of enzymes, however
the metabolic products of each pathway are structurally
and functionally distinct. EPA and AA are substrates for
the synthesis of a group of inflammatory mediators
including thromboxanes (TX), leukotrienes (LT), and
prostaglandins (PG), collectively referred to as eicosa-
noids. Because the typical Western diet contains a much
greater proportion of n-6 PUFA to n-3 PUFA, the mem-
branes of most cells contain large quantities of AA, thus, it
is typically the principle precursor for eicosanoid produc-
tion [18]. AA metabolism yields 2-series PGs and 4-series
LTs, highly active agents of inflammation, whereas EPA
metabolism results in 3-series PGs and 5-series LTs, far
less potent prostanoids by comparison [19].
Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) are
enzymes required for PG and LT synthesis, respectively.
Competition between n-6 and n-3 PUFA for enzymatic
metabolism occurs for both PG and LT synthesis. Compe-
tition by EPA results in decreased production of TXA2 and
LTB4, and PGE2 metabolites, which ultimately reduces
platelet aggregation, vasoconstriction, and leukocyte
chemotaxis and adherence [20]. In addition, metabolism
of EPA gives rise to less potent eicosanoids [19]. A concur-
rent rise in TXA3, prostacyclin PGI3, and LTB5 results,
inhibiting platelet aggregation and vasoconstriction and
promoting vasodilation [20]. It is not difficult to associate
these metabolic products and their corresponding effects
with beneficial outcomes related to CVD. A decrease in
platelet aggregation reduces the development of athero-
sclerotic plaques by making blood less viscous and
decreases the likelihood of thrombus formation.
Increased vasodilation promotes blood flow with reduced
resistance, thus decreasing the likelihood of endothelial
damage and plaque initiation.
Recent studies have identified several new groups of medi-
ators that exert anti-inflammatory actions, via derivation
from COX-2; Lipoxins (LXs) from AA, E-series resolvins
from EPA [21-23] and D-series resolvins, docosatrienes
and neuroprotectins from DHA [24-26]. LXs and resolvins
act as anti-inflammatory mediators by assisting in the res-
olution of inflammatory events and assisting with the
clearance of cellular debris from the site of inflammation
[27]. They also suppress IL-1, IL-2, IL-6 and TNF-alpha
production by T cells [28-31], thus functioning as endog-
enous anti-inflammatory agents. Neuroprotectin D1 pos-
sesses anti-inflammatory and neuroprotective
characteristics [32,33] and has been shown to promote
wound healing [34] and brain cell survival [35,36]. While
this area of research requires more detailed investigation,
these novel classes of inflammatory mediators may be
implicated in a variety of health-related conditions.Lipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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While the conversion of ALA to its long-chain derivatives
is important, human and animal studies reveal that a
major metabolic fate of ALA metabolism is β-oxidation.
Over a 24 hour period, 20% of palmitic, stearic, and ara-
chidonic acids orally administered to rats were expired as
CO2, compared to 60% for labelled ALA [37]. In humans,
the values are slightly less, with 16–20% of ALA being
expired as CO2 over 12 hours [6,38]. This corresponds
with a recent tracer study in men consuming a control
meal that included 700 mg of labelled ALA, which dem-
onstrated that ~34% of the labelled ALA was recovered as
CO2 over 24 hours [39]. In a subsequent study using test
diets with elevated levels of ALA (10 g/d) or EPA+DHA
(1.5 g/d) consumed for 8 weeks, it was observed that the
amount of expired label in the second tracer study was not
affected by increasing either ALA or EPA+DHA intakes
[39]. In addition, a separate study in humans determined
that ALA was the most highly oxidized fatty acid when
compared to other 18 carbon fatty acids including
linoleate, elaidate, oleate, and stearate [40]. Other meta-
bolic routes of ALA include carbon recycling for de novo
lipogenesis in the brain and other tissues [41].
Interestingly, whole-body ALA conversion to DHA in rats
has been found to be higher than originally predicted
[42,43]. In fact, in one study, the hepatic (representative
of whole-body) DHA synthesis rate in rats intravenously
infused with labelled ALA was approximately 30 times
higher as compared to previously published rat brain
DHA consumption rates [42]. Another study found
hepatic DHA synthesis from ALA was only 5–10 fold
higher than brain DHA consumption rates [43]. While
there is discrepancy in ALA conversion rates in rats, these
studies imply that dietary ALA could sufficiently supply
the brain with DHA in the absence of exogenous DHA
intake. It is important to note that the hepatic DHA syn-
thesis rates observed for rats do not extend to humans
[44]. The higher rates reflect a more efficient ALA elonga-
tion process in mice and rats, therefore results using these
experimental models should be carefully considered
when extrapolating effects in humans.
Differential effects Of N-3 Pufa In Cancer
A growing body of literature exists surrounding n-3 PUFA
and cancers of the breast and prostate. Animal studies sug-
gest a beneficial effect, however the relationship in
humans is more complex. Many human studies fail to dif-
ferentiate between ALA, EPA, and DHA when reporting
effects of n-3 PUFA on cancer risk, or a fish oil blend is
used, preventing evaluation of individual effects of EPA
and DHA. Despite these challenges, important mechanis-
tic insights are continually being identified that will even-
tually help elucidate the individual effects of n-3 PUFA in
two of the most common forms of cancer worldwide.
Prostate Cancer
ALA
The relationship between ALA and prostate cancer has gar-
nered considerable attention, in part due to unexpected
study results reporting positive correlations between ALA
intake and prostate cancer risk [45-48]. The literature is
not without inconsistencies, however, as reviewed [49].
ALA intake was recently assessed by dietary questionnaire
in 6 observational studies [45-48,50,51], and by blood
and/or prostate tissue analysis in another 5 studies [52-
56]. Of the questionnaire based studies, 4 found positive
associations between ALA intake and prostate cancer risk
[45-48], while no association was found in two [50,51].
In studies which measured circulating levels of ALA in
blood, 2 found positive associations [55,56], while no sig-
nificant relationship was established in two other studies
[52,54]. In contrast, the single study that measured pros-
tate tissue levels of ALA found a negative association
between ALA status and risk of prostate cancer [53]. Two
additional questionnaire based studies found no associa-
tion between ALA intake and prostate cancer risk. One
assessed pre-clinical prostate cancer cases [57] while the
other was a nested case-control study within the Alpha-
Tocopherol, Beta-Carotene cohort in Finland [58]. Inter-
estingly, of the studies that identified positive associations
between ALA and prostate cancer risk, the association was
often strong and persisted or was strengthened after
adjusting for potential confounding variables including
total energy and fat intake, animal fat, saturated and
monounsaturated fatty acids, LA, and red meat consump-
tion. Adjusted odds ratios (OR) or relative risks (RR) var-
ied from 1.3 to 4.3, and the association was found in
populations from different countries and with diverse die-
tary habits, as reviewed [58,59]. One interpretation of
these intriguing results could be that high levels of ALA are
associated with increased prostate cancer risk because it
reflects poor conversion to EPA and DHA, which have
demonstrated anticancer effects.
While observational studies have offered insight into ALA
and prostate cancer risk, there are inherent weaknesses
associated with the study designs that limit their utility,
including confounding parameters and biases relating to
dietary recall and selection and classification of patients.
More importantly, these observational studies do not
demonstrate causality. Perhaps of more clinical relevance
are the flaxseed supplementation studies recently con-
ducted in men with prostate cancer awaiting surgery
[60,61] or in men with benign prostatic epithelium [62].
These studies consistently support a protective effect of
flaxseed supplementation (30 g/d for 30–180 d) by reduc-
ing cell proliferation [60-62] and increasing apoptosis
[60]. Moreover, a decrease in Prostate-Specific Antigen
(PSA) following flaxseed administration was observed in
some of the supplementation studies [60,62]. It is difficultLipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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to draw conclusions about the effectiveness of ALA from
these studies, however, as other components of flaxseed
may contribute to the observed outcomes and all supple-
mentation studies were conducted in combination with a
low-fat diet. More controlled investigations of this nature
are warranted, given the potential clinical utility of sup-
plementation studies in men with prostate cancer or who
are at increased prostate cancer risk due to elevated PSA
levels or family history.
Animal data on ALA and prostate cancer is also limited,
possibly due to inter-species diversity of anatomy, bio-
chemistry, and pathology of the prostate gland [63]. Sev-
eral studies have assessed tumorigenesis in mice, showing
reductions in prostate tumour growth in mice fed EPA-
and DHA-rich fish oil [64-66] but not in mice receiving
ALA-rich linseed oil [64]. Similarly, ALA-rich perilla oil
did not attenuate the incidence of prostate carcinoma in
cancer-induced rats as compared to corn oil-fed rats [67].
Inconsistencies in the literature exist with in vitro investi-
gations as well. This is complicated by the fact that exper-
imental outcomes are derived from heterogeneous study
conditions including differences in cell lines, growth con-
ditions, and fatty acid concentrations. A number of stud-
ies have demonstrated an anti-cancer effect of ALA on
prostate cancer cells in vitro. ALA suppressed cell prolifer-
ation and inhibited production of Urokinase-type plas-
minogen activator, an enzyme responsible for promoting
invasion and metastasis of cancer in human DU145 cells
[68]. In a separate study on the same cell line, physiolog-
ical concentrations of ALA increased cell death [69]. In the
PC-3 human prostatic cell line, however, ALA increased
cell growth at concentrations ranging from 0.003 to 25
uM [70-73]. In contrast, EPA and DHA inhibited growth
of these cells. ALA was shown to promote growth of
human LN-CaP and TSU prostate cell lines, rat metastatic
Mat-Ly-Lu cells, and the rat non-metastatic EPYP1 epithe-
lial cell line [72], but had no effect on the growth of rat
prostate epithelial cell lines EPYP2 and EPYP3. Overall,
there is no clear association between ALA and prostate
cancer in human, animal, or cell culture models and more
research is warranted to clarify the effect of ALA in prostate
tissue.
EPA and DHA
In contrast to ALA, there is some evidence suggesting a
protective role for EPA and DHA in prostate cancer. In
vitro studies have identified dose-dependent inhibition of
human cancer cell growth [73] and repression of PSA [74]
in PC-3, DU 145, and LNCaP prostate cancer cell lines.
Further, DHA alone or in combination with a low-dose
pharmacological COX-2 inhibitor (celecoxib) reduced
cell growth and induced apoptosis in prostate cancer cell
lines LNCaP, DU145, PC-3 and rat prostate tumour cells
[75,76]. These results suggest a unique COX-2 independ-
ent mode of action of DHA+celecoxib on prostate cancer.
The seemingly protective effects of EPA+DHA observed in
prostate cancer cell lines extend similarly to rodent stud-
ies. Nude mice with transplanted DU-145 human pros-
tatic tumour cells displayed decreased tumour incidence
and growth when fed diets supplemented with
EPA+DHA-rich fish oil (17–20.5% w/w) [64-66]. Several
studies in rodents have reported decreased prostate
tumour burden with n-3 PUFA supplementation [77-79],
but fail to detail the specific fatty acid composition of the
n-3 PUFA in the diets, making it difficult to assess the
effects of EPA and/or DHA in these investigations.
A recent review of prospective cohort studies of n-3 PUFA
and prostate cancer risk in humans found that, of 7 stud-
ies evaluating risk relative to fish, marine oil or EPA or
DHA consumption, 2 demonstrated either a favourable
effect or a trend towards a favourable effect and the rest
showed no association [80]. A significant positive associ-
ation between a high LA:DHA ratio has been shown to
enhance prostate cancer risk [81], eluding to a protective
effect of DHA or a detrimental effect of LA on prostate car-
cinogenesis. The study outcomes suggest a need to take
relative intakes of n-3 and n-6 PUFA into account when
evaluating prostate cancer risk for a more comprehensive
assessment of potential fatty acid effects. Reduced prostate
cancer risk was shown to be associated with high erythro-
cyte phosphatidylcholine levels of both DHA and EPA
[82]. In contrast, in a separate study a positive association
was observed between intakes of EPA and DHA and risk
of prostate cancer in initially cancer-free men aged 45–73
years [83]. While in vitro and rodent studies more consist-
ently support a potentially protective effect of EPA+DHA
on prostate carcinogenesis, determining the mechanisms
by which they confer their benefits will be invaluable for
improving our understanding in human studies.
Breast Cancer
ALA
Recent observational studies have assessed breast cancer
risk and breast adipose tissue fatty acid composition. Two
case-control studies compared women with invasive non-
metastatic breast carcinoma and women with benign
breast disease [84,85]. In addition to identifying an
inverse correlation between breast adipose tissue ALA and
breast cancer risk, one of the studies noted a significant
decrease in risk for women in the highest tertile of ALA
intake [85]. Another study assessing the effects of ALA
consumption on breast cancer risk reported a reduced risk
for women in the highest versus lowest quintiles of ALA
intake [86]. While these results are encouraging, caution
must be used when interpreting data from observational
studies, as correlation does not equal causation. MoreLipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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studies on ALA and breast cancer risk in human subjects
are warranted.
In rodent models, a trend towards a protective effect of
ALA on mammary tumorigenesis has been observed. A
high ALA diet significantly inhibited spontaneous mam-
mary tumorigenesis in mice [87] and feeding ALA-rich lin-
seed oil to mice reduced growth of mammary tumours
and metastasis [88]. Similar reductions in tumour growth
rate and metastasis resulted when a basal diet supple-
mented with ALA-rich flaxseed was fed to nude mice
injected with human breast cancer cells [89]. Reduced
tumorigenesis was accompanied by downregulation of
insulin-like growth factor I and epidermal growth factor
receptor expression, offering potential mechanistic insight
into the effects of ALA. Flaxseed administered to ovariect-
omized mice with established MCF-7 tumours demon-
strated attenuation of soy protein isolate-induced tumour
biomarkers after 25 weeks [90]. In a separate study in ath-
ymic mice with established MCF-7 tumours, tamoxifen in
combination with a diet supplying 10% energy as flax-
seed, regressed tumours to 55% of the pre-treatment
tumour size [91]. Interestingly, tamoxifen alone achieved
only a 6% reduction in tumour size, compared to pre-
treatment values, suggesting an important anti-prolifera-
tive, pro-apoptotic role of ALA. Finally, in a study evaluat-
ing the effect of dietary beta-carotene combined with an
ALA- or LA-rich diet in rats, researchers concluded that an
adequate content of dietary ALA is required for a protec-
tive effect of beta-carotene in mammary carcinogenesis
[92]. The results from ALA research on mammary tumori-
genesis in rodents are encouraging and more work is war-
ranted in this area to help clarify mechanisms by which
individual fatty acids affect mammary gland physiology
and pathology.
Few studies have investigated the effects of ALA on breast
cancer in vitro. A study that assessed the chemoprotective
potential of unsaturated fatty acids and vegetable oils
observed a seemingly dual role for ALA in 17-beta-estra-
diol epoxidation [93]. ALA prevented formation of the
potential cancer initiator 17-beta-estradiol epoxide under
normal conditions. When activated by an epoxide-form-
ing oxidant, however, ALA inhibited nuclear RNA synthe-
sis, suggesting it might be a potential post-epoxidation
carcinogen. Similarly, another study had difficulty charac-
terizing the role of ALA in both estrogen dependent and
independent breast cancer cells, citing a variable effect of
ALA on cell proliferation depending on the cell line
assessed [94]. ALA significantly inhibited cell growth in
ER-negative MDA-MB-231 and HBL-100 human breast
tumour cells but not in ER-positive MCF-7 cells. A trend
towards a decrease in cell growth in the other ER-positive
cell lines ZR-75 and T-47-D by ALA did not reach statisti-
cal significance [94]. Authors did identify, however, that
the addition of ALA, EPA and DHA to breast cancer cells
increased the content of conjugated dienes and lipid
hydroperoxides in cellular lipids, which was significantly
correlated with the capacity to arrest cell growth.
EPA and DHA
The data for EPA and DHA in breast cancer are equivocal.
Some case-control studies have demonstrated significant
inverse associations between breast cancer risk and dietary
intake of n-3 PUFA from fish and fish oils. Bagga et al.
showed a decreased risk of breast cancer development
with higher EPA and DHA consumption [95]. Similarly,
an investigation assessing erythrocyte n-3 PUFA levels
from fish consumption identified an inverse association
with breast cancer risk [17] and another assessment of
erythrocyte fatty acid composition found the inverse asso-
ciation significant only for EPA and total n-3 PUFA con-
tent [96]. Contrary to these findings, however, a large
study of post-menopausal women concluded that
increased fish consumption and thus, increased EPA and
DHA intake, was associated with elevated breast cancer
rates, but only in ER+ breast cancers [97]. Others assessing
fish consumption and breast cancer have found no signif-
icant associations [98,99].
EPA and DHA have demonstrated protective effects in a
number of rodent models of breast cancer. Fish oil supple-
mentation decreased tumour growth rates and the extent
of metastases in BALB/cAnN and nude mice [100,101].
Similarly, supplementing in nude mice with EPA and
DHA independently produced comparable results [102].
Chemically-induced mammary tumorigenesis has been
studied in rats with similar outcomes. Corn oil increased
growth of DMBA-induced mammary tumours, while
menhaden oil inhibited their development at correspond-
ing supplementation levels [103]. In a separate investiga-
tion, menhaden oil at 20% of energy reduced tumour
incidence and prolonged tumour latency, with authors
determining that EPA was significantly inversely related to
mammary tumour development [104]. DHA has also
been shown to decrease mammary tumour incidence
[105], yielding a 60% increase in BRCA1 protein level, the
product of a major tumour suppressor gene. Fish oil sup-
plementation has also been shown to enhance the thera-
peutic effects of tumour inhibitors doxorubicin and
mitomycin C in mice [106,107].
Cell culture studies also support the protective role of EPA
and DHA in breast cancer. Anti-proliferative effects have
been observed for both EPA and DHA in human mam-
mary epithelial cells, with a higher efficiency noted for
DHA [108]. Moreover, both EPA and DHA inhibit MCF-7
cell growth by 30 and 54%, respectively [109], and they
have decreased FAS activity [110], a possible oncogene
that is up-regulated in breast cancers [111]. A study of BT-Lipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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474 and SkBr-3 breast cancer cells, which naturally
amplify the HER-2 oncogene, found that DHA downregu-
lated HER-2 action [112]. Another in vitro investigation
identified dose-dependant cytotoxic effects of EPA and
DHA on human breast tumour cells [113] and arrested
tumour cell growth in numerous estrogen-dependent and
-independent cell lines [94]. The results from in vitro and
rodent studies support a protective effect of EPA+DHA on
mammary tumourigenesis, however a clear definition of
their role in human breast cancer is still lacking, which
requires additional mechanistically focused studies.
Cancer-Specific Mechanisms of n-3 PUFA
ALA
ALA, mainly as a component of flaxseed, has been shown
to decrease angiogenesis and metastasis in some studies
[114,115], but not others [116]. In vitro, Menendez et al.
studied breast cancer cells naturally amplifying the HER-2
oncogene and found that ALA suppressed HER-2 coded
p185 Her-2/neu oncogene expression [117]. While the
precise mechanism responsible for the suppression is
unknown, it was determined to have occurred at the tran-
scriptional level, suggesting a fundamental change in RNA
synthesis. Further, dose-dependant cytotoxic capabilities
of ALA on human breast tumour cells have been identified
[113], offering potential ways in which this fatty acid
might be anti-carcinogenic.
EPA and DHA
In addition to the anti-inflammatory mechanisms
described previously, EPA-derived products of COX and
LOX decrease tumour growth [118,119] and EPA and
DHA individually decrease activation of oncogenic tran-
scription factors [120,121]. They inhibit angiogenesis
[122-126], downregulate expression of Bcl-2 family genes
[127,128], and promote apoptosis by downregulating NF-
kB [129]. DHA has also been shown to halt tumour
growth by promoting differentiation of breast cancer cells
[130], which prevents further cell multiplication. Further,
EPA and DHA incorporation into membrane rafts (MRs)
reduces total cholesterol content and ultimately enhances
apoptosis in epithelial, prostate and cancer cells via Akt
inactivation [131]. Antiproliferative action and apoptosis
has also been demonstrated by EPA and DHA through
inhibition of HMG-CoA reductase [132], which inhibits
the mevalonate pathway and, ultimately, the function of
oncogenic forms of Ras.
Differential effects of N-3 Pufa in Insulin 
Resistance
Insulin resistance plays a role in several chronic diseases
including metabolic syndrome and type 2 diabetes (T2D).
There is a growing body of evidence suggesting an inverse
association between n-3 PUFA and insulin resistance (IR).
Anti-diabetic effects of PUFA have been observed, includ-
ing increased basal metabolic rate and fat oxidation
[133,134], however some of these findings have resulted
from studies comparing polyunsaturated:saturated fatty
acid intake. While identifying differences in energy sub-
strate utilization based on the saturation ratio of dietary
fatty acids is important, it is of interest to determine any
fatty acid-specific differences that might exist among n-3
PUFA.
ALA
To date, few studies have examined the impact of ALA
consumption on markers of T2D and IR. In one investiga-
tion, T2D subjects received safflower oil or 60 mg/kg body
weight/day flaxseed oil, translating to roughly 5.5 g ALA/
day. After 3 months of supplementation, no significant
changes were observed in fasting blood glucose, insulin,
or HbA1c [135]. In a separate study, the inflammatory
marker C-reactive protein (CRP), but not IR, was inversely
related to blood plasma phospholipid and cholesteryl
ester levels of ALA, as well as EPA and DHA in persons
with metabolic syndrome [136]. Two additional studies
failed to note any significant change in insulin, and glu-
cose after supplementing T2D subjects with 35 mg/kg
body weight ALA in the form of flaxseed oil for 3 months
[137,138]. In contrast, Enriquez et al. observed a positive
correlation between fasting insulin levels, IR, and erythro-
cyte ALA content in a comparable T2D population [139].
Based on the limited data available, no conclusions can be
made regarding ALA and markers of T2D, although pre-
liminary evidence does not seem to support an insulin-
sensitizing role of ALA in T2D. Comparable studies on
healthy individuals would be useful to identify any poten-
tial beneficial preventative effects of ALA on IR or T2D.
To the best of our knowledge there are no cell culture stud-
ies investigating the effect of ALA on IR. Only a few rodent
studies have reported effects of ALA. Recently, Javadi et al.
assessed the effects of 12% w/w ALA:4% w/w LA on body
composition in mice. After 35 days, the proportion of
body fat was not influenced by increased dietary ALA:LA,
as compared to high LA:ALA or low-fat diets [140]. Plasma
total cholesterol and phospholipids were significantly
lower in the high ALA compared to the high LA group and
the activities of enzymes in the fatty acid oxidation path-
way were significantly raised in both PUFA groups vs. the
low-fat diet group. There were, however no differences in
fatty acid oxidation or lipogenic enzymes between the
high ALA and LA group, indicating no significant influ-
ence of ALA on body composition. In contrast, Ghafooru-
nissa et al. demonstrated that substituting one third
dietary LA with ALA significantly improved insulin sensi-
tivity and decreased blood lipid levels in sucrose-induced
IR rats [141]. Similarly, ALA-rich chia seed prevented the
onset of dyslipidaemia and IR in rats fed a sucrose-rich
diet for 3 weeks [142]. Further, dyslipidaemia and IR inLipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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rats receiving a sucrose-rich diet for 3 months were nor-
malised and visceral adiposity was reduced when they
were fed chia seed for the last 2 study months. While the
extent to which ALA, specifically, was responsible for the
beneficial effects seen in the chia seed group is unknown,
the results are encouraging and warrant further investiga-
tion. ALA has also significantly improved insulin sensitiv-
ity and glycemic response in male ob/ob mice [143].
At present, there are too few studies on ALA in this area of
research to delineate its effects. Further, animal studies
have used varying ALA concentrations and in varying
ratios with LA, making it difficult to accurately define a
role for ALA, specifically. As well, use of high levels of ALA
in rodent studies should be cautiously interpreted, as they
may not be physiologically relevant in humans. It can be
hypothesized that, at high enough concentrations, ALA
could be converted into levels of EPA and DHA that reach
therapeutic levels, particularly given the current discrep-
ancy regarding the efficiency of ALA conversion to its
longer chain derivatives in rats [42,43]. Apart from its
ability to convert to EPA and DHA, however, it would be
of value to elucidate any specific bioactive effects ALA
might have in relation to T2D and its related pathologies.
Recently developed mouse models, including a delta-6-
knockout mouse that inhibits the conversion of ALA to
EPA and therefore DHA [144], could be highly useful in
this regard.
EPA and DHA
Findings involving fish oil effects on human body compo-
sition and IR vary depending on the health of the subjects
and the nature of the study. As a result, it has been difficult
to determine the effects of EPA+DHA on diabetes-related
parameters. Body fat mass decreased and lipid oxidation
was concurrently stimulated in healthy volunteers when 6
g/d visible fat was substituted with 6 g/d fish oil [133].
Browning et al. recently reported that after 12 weeks of
EPA and DHA supplementation in overweight women, a
significant reduction in inflammatory markers was
observed [145], although it was unclear whether the
seemingly insulin-sensitizing effects of n-3 PUFA were
mediated through inflammatory mechanisms. Another
study, however, did not identify any correlation between
dietary intakes of EPA and DHA and IR in T2D subjects, as
measured by HOMA-R [146]. It appears as though PUFA
from marine sources potentially contribute to favourable
modifications of diabetes-related parameters, possibly by
increasing insulin sensitivity, decreasing inflammatory
mediators, or altering lipid metabolism in lean adults.
This benefit, however, does not seem to extend to obese or
T2D subjects.
Animal studies involving EPA+DHA and IR tend to be
more consistent and support an anti-diabetic effect.
Numerous rodent studies have shown that EPA improves
IR in several models of obesity and diabetes [147-149]
and elevated systemic concentrations of insulin-sensitiz-
ing adiponectin [150] as well as an improved response to
a glucose load [151] were reported in mice fed high fat
diets enriched in EPA+DHA. Several studies have assessed
fish oil feeding in sucrose-fed rats and noted attenuated
peripheral IR, hyperglycemia, and fat pad mass [152,153]
as well as increased insulin-stimulated glucose transport
[154] in supplemented animals. EPA as well as DHA pre-
vented alloxan-induced diabetes and restored the anti-
oxidant status of various tissues to normal range in rats
[155] and were shown to be more effective than ALA at
lowering plasma glucose and insulin levels and improving
insulin sensitivity [156]. When a 60% energy from fruc-
tose diet was supplemented with 4.4% energy from fish
oil, the hyperlipidemia that occurred in unsupplemented
rats was prevented, however hyperinsulinemia was not
[157]. The findings of a study on male ob/ob mice, how-
ever, concluded that EPA+DHA had no effect on insulin
sensitivity or fasting blood glucose [158].
Many in vitro studies assessing IR have cultured adipocytes
from insulin resistant and insulin sensitive rodents that
have been fed diets differing in EPA+DHA content. Several
of these studies demonstrate improved insulin-stimulated
glucose transport, oxidation, and incorporation into total
lipids in the adipocytes of normoinsulinaemic rats fed a
sucrose-rich diet including 30% of energy as fish oil
[159,160]. Similarly, rats fed a sucrose-rich diet long-term
for 120 d were hypertriglyceridemic, insulin resistant, and
had abnormal glucose homeostasis [153]. When 7% w/w
fish oil was isocalorically substituted for corn oil from day
90–120, the inhibitory effect of the high-sucrose diet on
the antilipolytic action of insulin was corrected and the in
vitro-enhanced basal lipolysis was reduced [153]. An
investigation by Baker and Gibbons also supports a
favourable role of dietary fish oil with respect to IR in rat
hepatocyte cultures [161]. The hepatocytes from rats fed
an 18% w/w fish oil diet for 2 weeks demonstrated signif-
icantly altered sensitivity of insulin to some aspects of in
vitro hepatic fatty acid and glycerolipid metabolism [161].
Compared to hepatocytes from rats fed a low-fat or olive
oil-containing diet, fish oil feeding abolished the inhibi-
tory effect of insulin on the oxidation of exogenous oleate.
Compared to the olive oil and low-fat groups, however,
the fish oil-fed group had little to no effect on insulin's
ability to stimulate the incorporation of oleate into trig-
lycerides (TG). There was also no change in the sensitivity
of VLDL TG secretion to inhibition by insulin in the fish
oil group [161]. Thus, dietary supplementation with fish
oil might differentially affect the metabolic pathways of
the liver, however until more research is done, it will not
be clear exactly how EPA+DHA are implicated mechanis-
tically in IR.Lipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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IR-Specific Mechanisms of n-3 PUFA
n-3 PUFA are proposed to reduce the risk of insulin resist-
ance in multiple ways, few of which seem to be differen-
tially affected by the 3 fatty acids.
ALA
While there are no clear lipid-specific mechanisms by
which ALA might affect insulin resistance, one investiga-
tion assessing the effects of ALA in vitro and in vivo suggests
a potential anti-oxidant, anti-cytotoxic role of this fatty
acid. Prior exposure of an insulin-secreting rat insulinoma
cell line to ALA in culture was shown to prevent alloxan-
induced cytotoxicity and apoptosis [155]. In the same
study, prior supplementation with ALA also prevented
alloxan-induced diabetes in live rats and restored anti-oxi-
dant status to normal range in various tissues. The anti-
oxidant action of ALA is encouraging, as oxidant stress is
typically elevated in diabetics. The following effects noted
for EPA and DHA also extend to ALA, including upregula-
tion of insulin receptors and PPARs and downregulation
of NF-kB. The impact of EPA and DHA on these parame-
ters, however, tends to be more potent.
EPA and DHA
EPA and DHA are preferentially incorporated into cell
membranes, thus increasing membrane fluidity. This, in
turn, has been shown to increase the number of insulin
receptors on the cell membrane and their affinity to insu-
lin [162]. Upregulating insulin receptors decreases insulin
resistance and favourably modifies an individual's glyc-
emic response, an effect that could potentially delay or
prevent onset of T2D. Transcription factors have also been
implicated in IR. NF-kB activation of endothelial cells has
been demonstrated in response to hyperglycemia, how-
ever EPA and DHA have been shown to downregulate NF-
kB [163]. This could potentially mediate some of the vas-
cular complications that result from chronically elevated
glucose levels seen in diabetics. Further, PPARγ has been
implicated in the etiology of IR, as it increases the expres-
sion and translocation of GLUT-1 and GLUT-4, thereby
facilitating glucose uptake in adipocytes and muscle cells
[164]. EPA and DHA act as ligands for PPARs and thus,
may have an anti-diabetic role. Moreover, stimulation of
PPARγ inhibits expression of IR-promoting cytokines,
while concurrently triggering an increase in plasma con-
centrations of adiponectin [165]. This has the net result of
decreasing blood levels of glucose by improving insulin
sensitivity and decreasing liver glucose production [166].
Differential effects of N-3 Pufa in Cardiovascular 
Disease
Perhaps the most robust evidence for potentially benefi-
cial effects of EPA and DHA has resulted from research
surrounding cardiovascular health [167-171]. In contrast,
a clear relationship between cardiovascular disease (CVD)
and ALA intake in humans is lacking.
ALA
In an attempt to determine potential differential effects of
n-3 PUFA, Singh et al. compared the effects of feeding
ALA-rich mustard seed oil, fish oil, and a non-oil placebo
to 360 patients hospitalized for suspected acute myocar-
dial infarction (MI) [172]. They found that both oil sup-
plements reduced CVD outcomes, including total cardiac
events and non-fatal infarctions, but only the effects of the
fish oil reached statistical significance. Further, fish oil but
not mustard seed oil reduced the number of total cardiac
deaths reported [172]. Natvig et al. randomly assigned
13,578 healthy subjects to receive 10 ml flaxseed oil (5.5
g ALA) or 10 ml sunflower seed oil (0.14 g ALA) daily for
a year and observed no significant cardiovascular benefit
of ALA supplementation [173]. Conversely, several stud-
ies assessing the effects of ALA intakes of between 1.8 and
6.3 g/d [174-176] reported significant reductions or
trends toward reduced numbers of CVD events [174-176].
The validity of some trials mentioned here [172,175] has
been questioned by reviewers, citing multiple methodo-
logical issues such as inadequate randomization conceal-
ment, the use of a non-oil placebo, and even calculation
errors in the published results [177,178]. Accordingly,
assertions cannot be confidently made regarding the
potential of ALA to have cardioprotective effects, despite
some intriguing study findings.
A recent meta-analysis was conducted to determine
whether ALA supplementation could modify 32 estab-
lished and emerging cardiovascular risk markers [179]. Of
the 14 studies reviewed, only 3 outcomes – fibrinogen,
fasting blood glucose, and HDL cholesterol – were modi-
fied by at least 4 weeks of ALA supplementation, prompt-
ing authors to conclude that ALA supplementation to
reduce CVD could not be recommended [179]. In con-
trast, a meta-analysis of 5 prospective cohort studies and
3 clinical trials assessing ALA intake and risk of fatal coro-
nary heart disease concluded that ALA intake might
reduce heart disease mortality [180].
Several independent analyses of the NHLBI Family Heart
Study have identified multiple inverse associations
between ALA and CVD risk factors including prevalence of
hypertension, coronary artery disease, plasma TG, and
carotid atherosclerosis [181-184]. Some studies have
demonstrated cardioprotective effects of ALA on risk of MI
[176,185-187], stroke [188], and ischemic heart disease
[189]. Others have found no significant association
between MI and ALA [190]. The inconsistencies in these
study results is not entirely unexpected, however, as there
is significant heterogeneity in the study populations and
designs. In addition, several of the studies assessed nutri-Lipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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ent intake by dietary questionnaire, which can yield errors
in food intake estimates and nutrient content calculations
of specific foods. Moreover, background EPA, DHA and/
or fish consumption might mask the effects of ALA intake
[186], offering a potential explanation as to why some
researchers have found no associations between nonfatal
MI and ALA intake.
EPA and DHA
Mounting evidence from epidemiological and dietary
intervention trials supports the cardioprotective role of
EPA+DHA-rich fish oil [167-171]. Their demonstrated
beneficial effects include, but are not limited to regulation
of eicosanoid production from AA, plasma triacylglycerol-
and blood pressure-lowering effects, regulation of ion flux
in cardiac cells, and regulation of gene expression via the
peroxisomal proliferation system, as reviewed by Sinclair,
et al. [191]. It is well-known that EPA+DHA favourably
modify serum markers of CVD risk by reducing TGs and
increasing HDL-cholesterol and there was a meta-analysis
on this topic in 2006 [192]. In particular, their TG-lower-
ing ability has been demonstrated at intakes that are
achievable from the diet [167-169,171], providing com-
pelling evidence for effective dietary CVD therapy.
While the majority of investigations assessing CVD and
fatty acid intake suggest a beneficial effect of marine-
derived PUFA, Burr et al. reported that fish oil supple-
ments but not fish intake increased the incidence of sud-
den cardiac death in patients with angina [193]. However,
as recently summarized, the research collectively shows
beneficial effects of n-3 PUFA from both marine and plant
sources on sudden cardiac death incidence [170]. Despite
the study by Burr and colleagues, the effectiveness of n-3
PUFA as an agent for the secondary prevention of cardio-
vascular events seems promising, following a recent
review of 4 secondary prevention trials [194]. All 4 trials
reduced secondary cardiac events with between 1.0 and
1.8 g/d fish oil capsules or with 1 serving of fish/d or ALA
supplementation. Further, results were similar irrespective
of form of n-3 PUFA intake, providing a practical and
attractive option for widespread CVD therapy. The cardio-
protective effects of EPA and DHA from marine sources
are well documented and offer a promising avenue by
which North Americans can reduce their risk of CVD
through dietary means.
CVD-Specific Mechanisms of n-3 PUFA
Perhaps the most robust evidence for the health-promot-
ing effects of fatty acids is derived from studies assessing
the relationship between n-3 PUFA and CVD [167-171].
As a result, much work has been done in this area and,
increasingly, a focus on differentiating between the effects
of ALA and EPA+DHA is occurring.
ALA
Some have speculated that the seemingly protective effects
of ALA may have more to do with cardiac function than
with plasma lipids [5]. While ALA supplementation has
decreased total cholesterol, effects have been minimal (2
or 8% reduction from baseline at 3.5 or 5.3% energy as
ALA, respectively) [195,196]. ALA has, however, signifi-
cantly reduced the incidence of arrhythmias and cardiac
mortality in rats [197], enhanced arterial compliance in
obese subjects [198,198], and decreased C-reactive pro-
tein, IL-6, and serum amyloid A – inflammatory markers
implicated in atherogenesis in males with dyslipidaemia
[199]. While effects of ALA on platelet aggregation and
thrombosis are inconsistent [200], there seems to be an
overall protective effect of this fatty acid on cardiac out-
comes in humans and rodents that is not explained solely
by modest reductions in cholesterol levels.
EPA and DHA
EPA and DHA are potent hypotriacylglycerolaemic agents.
Analysis of 36 human crossover studies found 3–4 g/d
EPA+DHA intake yielded a plasma TG decrease of 24%
and 35% in normolipidaemic and hypertriacylglycerolae-
mic subjects, respectively [201]. This is thought to be due
to both decreased TG synthesis, likely via impairment of
the SREBP pathway [202], and increased TG clearance by
EPA+DHA. N-3 PUFA from marine sources have also
demonstrated antiarrhythmic effects. At 2.4 g/d,
EPA+DHA significantly reduced ventricular premature
complexes in patients with frequent ventricular arrhyth-
mia and at 4 g/d EPA+DHA, heart rate variability was
increased in survivors of MI, as reviewed by Wijendran et
al. [5]. Fish oil has improved arterial compliance and
endothelial function [203] and decreased blood pressure
in a dose-dependant manner [204]. Further, DHA but not
EPA significantly improved forearm blood flow and vas-
cular reactivity in hyperlipidaemic, overweight men [205].
Apart from these antiatherogenic properties, EPA+DHA
have demonstrated antithrombotic action, however not at
clinically relevant supplementation intake levels [5].
Potential global mechanisms of action
Currently, proposed mechanisms of how n-3 PUFA
impact physiological processes include: regulation of
inflammation, alteration of gene expression, modification
of membrane raft structure and function, and involve-
ment in other disease-specific pathways.
Membrane effects of n-3 PUFA
N-3 and n-6 PUFA compete not only for the same set of
metabolic enzymes, but also for incorporation into cell
membranes, where they influence membrane fluidity and
the function of membrane-bound constituents, including
receptors and enzymes. ALA, EPA, and DHA differentially
impart fluidity in cell membranes, however the individualLipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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n-3 PUFA effects have not been studied equally in this
area. The identification of abundant amounts of DHA in
the retina and brain has led to a greater proportion of
research on this fatty acid compared to ALA and EPA. As a
result, the effects of ALA and EPA in membranes are not
entirely clear.
ALA
In humans, increased membrane fluidity results following
ALA supplementation. At 0.9% of total energy, ALA
increased erythrocyte membrane fluidity in 29 supple-
mented monks [206], particularly when intake of myristic
acid, a saturated fatty acid, was reduced. Fluidity was
measured by labelling red blood cells with 16-doxylstear-
ate and subsequently calculating relaxation-correlation
time. ALA membrane enrichment has also been demon-
strated in vitro with various outcomes depending on the
cell line studied [207-209]. An important role for ALA in
skin and fur has also been investigated following the
observation that ALA (and LA) supplementation reduced
skin lesions in rats [210]. Subsequently, ALA enrichment
in skin and secretion onto fur has been noted in guinea
pigs [211], rats [212,213], and primates [214]. Proposed
roles for this fatty acid are to promote fur growth and to
offer protection of fur and skin from damage by sun,
water, and other agents, as reviewed by Sinclair et al.
[191].
EPA
EPA has demonstrated notable membrane modification
in immune cells. Immune cells are typically rich in AA,
which produces pro-inflammatory eicosanoids. Immune
cell fatty acid content can be modified, however, through
oral administration of EPA and DHA, which displaces AA
from the membranes [18]. EPA, specifically, has been
shown to inhibit AA release from phospholipids by phos-
pholipase A2 [215], effectively reducing the amount of
substrate available for the production of potent pro-
inflammatory eicosanoids. Altering immune cell fatty acid
composition can also influence phagocytosis, T-cell sig-
nalling, and antigen presentation capability, effects which
are likely mediated at the membrane level. While several
beneficial effects of ALA and DHA also have an anti-
inflammatory or immune component, EPA seems to be
particularly potent at decreasing inflammation. EPA may
also have an important role in bone development and
remodelling [216-220] and has been implicated in myelin
sheath membrane maintenance and stabilization [221],
as well as attenuating protein degradation in skeletal mus-
cle of cachectic cancer patients [222-224]. These EPA-spe-
cific effects, however, will not be covered in this review.
DHA
DHA is a key player in conferring fluidity to rhodopsin
disks in rod cells of the eye [225] and axons in the mam-
malian brain [226]. DHA has demonstrated an ability to
alter phase behaviour in cell membranes by distorting
packing by steric restrictions associated with the presence
of multiple rigid double bonds, which decreases mem-
brane stability [227]. There have also been numerous
reports linking DHA to increased membrane permeability
and a predisposition to undergo membrane vesicle forma-
tion and fusion [228]. These traits are proposed to be due,
in part, to looser lipid packing conferred by DHA in mem-
branes, which would facilitate deeper penetration of water
and other solutes in the bilayer and that acyl chain
unsaturation and membrane curvature combine to favour
fusion [227]. EPA also increases plasma membrane fluid-
ity of cells, but has been shown to accomplish this to a
lesser extent than DHA [229]. This is thought to be due to
its slightly shorter chain length and thus, reduced ability
to decrease membrane cholesterol content and increase
the unsaturation index in the plasma membranes.
In addition, a 'membrane pacemaker theory' has recently
been proposed, in which DHA-enriched membranes are
associated with high metabolic rates of tissues such as
heart and skeletal muscles [230,231]. The theory seems to
be successful at correlating n-3 PUFA status with meta-
bolic rates notably that, as membrane content of DHA
increases and the degree of polyunsaturation increases, a
corresponding increase in the activity of membrane-asso-
ciated processes is observed [232]. It has been proposed
that such membrane polyunsaturation increases the
molecular activity of many membrane-associated proteins
and consequently some specific membrane leak-pump
cycles and cellular metabolic activity.
Membrane Rafts
Lipid rafts, also termed lipid microdomains, detergent-
resistant membranes (DRMs), Triton-X insoluble mem-
branes, and membrane rafts (MR), are distinct plasma
membrane regions ~100 nm – 200 nm in diameter [233]
with reduced fluidity due to their enrichment in choles-
terol, glycosphingolipids, and phospholipids [234-236].
Caveolae, viewed as a subset of lipid rafts, are ~100 nm
diameter flask-shaped invaginations of the plasma mem-
brane, rich in cholesterol, glycosphingolipids, and the
cholesterol-binding protein caveolin [236,237]. Caveolae
involvement have been identified in studies on cancer
[238-241], IR [242-245], and CVD [246-250] and the
caveolae-specific protein caveolin is being implicated in
numerous signalling pathways as our understanding of
caveolae and its constituents expands.
Membrane rafts are thought to be key elements in signal
transduction, ion channel function, trafficking, and pro-
tein sorting [251-255] and are the target of many acylated
proteins [256-258]. The precise role rafts play, however,
remains to be determined. Similarly, the individual effectsLipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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of ALA on membrane raft structure and function requires
investigation. Indeed, there are currently no studies of this
nature. Experimentation in this area is necessary to iden-
tify mechanisms involved and pathways affected by die-
tary intake of ALA, and how they compare to those of its
longer-chain counterparts.
Alterations in dietary EPA and DHA intake modify lipid
raft structure due to their highly unsaturated nature and
inability to pack efficiently with the highly saturated acyl
side chains present in MRs. This, in turn, has resulted in
altered lipid raft function [259-261]. N-3 PUFA enrich-
ment of MRs has been demonstrated in mammary, colon,
epithelial, and prostate cells, affecting various signalling
pathways depending on the cell line involved [262,263].
EPA was recently shown to profoundly alter lipid compo-
sition and fatty acyl substitutions of phospholipids in
caveolae [264]. In the same study, investigators identified
EPA-induced translocation of eNOS from caveolae to sol-
uble fractions, accompanied by displacement of caveolin
from caveolae. In contrast, Bousserouel et al. concluded
that EPA (and DHA) treatment increased caveolin concen-
tration in caveolae, which correlated with smooth muscle
cell proliferation inhibition [265].
DHA has demonstrated an ability to alter lipid raft size
and distribution [266] and behaviour [227,267]. DHA
treatment markedly altered the lipid environment of cave-
olae in endothelial cells, resulting in selective displace-
ment of caveolin and eNOS [268], and inhibited cytokine
production and signalling [89,269], suggesting a role for
DHA-induced modifications of caveolae in atherosclero-
sis and other inflammatory conditions.
Inflammation
It is widely accepted that a chronically upregulated
inflammatory state is involved in the etiology of cancer,
IR, and CVD. As detailed previously, when n-3 PUFA
intake increases, a corresponding increase in AA antago-
nism occurs and the production of less inflammatory and
chemotactic derivatives results, decreasing an individual's
susceptibility to developing chronic inflammatory prob-
lems and related diseases.
ALA
Adhesion molecules including intracellular adhesion
molecule-1 (ICAM-1), vascular adhesion molecule-1
(VCAM-1), and E-selectin, upon upregulation, facilitate
the movement of immune cells into tissue and promote
inflammation. ALA has been shown to reduce plasma
concentrations of soluble E-selectin and VCAM-1 in
healthy human subjects [270]. Epidemiological studies
have further demonstrated reduced plasma concentra-
tions of markers of inflammation including C-reactive
protein and IL-1ra [271], as well as IL-6 and E-selectin by
ALA (at ~0.6 g/d) [272]. Intervention trials found similar
anti-inflammatory effects, although results were obtained
with high ALA intakes (5–15 g/d) [199,270,273-275].
Reductions in C-reactive protein and the adhesion mole-
cules and pro-inflammatory cytokines mentioned above
have been associated with reduced risk of CVD [276], sug-
gesting a potential mechanism of action for ALA in cardi-
ovascular health promotion.
EPA and DHA
Apart from altered eicosanoid production discussed previ-
ously, EPA inhibits IL-2 production by peripheral blood
mononuclear cells of some human donors [277] and both
EPA and DHA can inhibit IL-1B and TNFα production by
monocytes [278] and the generation of IL-6 and IL-8 by
venous endothelial cells [279,280]. Overproduction of
these cytokines can be dangerous, as they are implicated
in the pathological responses that occur in inflammatory
conditions. In addition, DHA decreased the surface
expression of multiple cell adhesion molecules on ex vivo
human venous endothelial cells [281] and impaired the
adherence of ligand-bearing monocytes [282].
Gene Expression
A more direct target proposed for n-3 PUFA is regulation
of the expression of genes involved in inflammation. ALA,
EPA and DHA have all demonstrated reduced cytokine-
mediated induction of expression of inflammatory genes
in culture [283]. The downregulation of inflammatory
gene expression has been proposed to be mediated
through nuclear factor kappa B (NF-kB) and peroxisome
proliferator-activated receptors (PPARs). NF-kB, in its
inactive form, has an inhibitory subunit (IkB) that, upon
stimulation, is phosphorylated and dissociates from the
rest of the inactive NF-kB heterotrimer. The remaining NF-
kB unit translocates to the nucleus and regulates the tran-
scription of target genes.
Unlike NF-kB, PPARs dimerise with retinoid-X-receptors
(RXRs) to regulate gene expression. PPAR-alpha and -
gamma are found in inflammatory cells and play impor-
tant roles in the liver and adipose tissue, respectively. They
are thought to be regulated, in part, by direct binding of
PUFA and eicosanoids and have been proposed to stimu-
late inflammatory eicosanoid degradation via induction
of peroxisomal B-oxidation. Alternatively, PPARs might
interfere with activation of other transcription factors,
including NF-kB, as previously reviewed [18].
ALA has demonstrated anti-inflammatory effects via NF-
kB suppression in multiple cell lines in vitro [284-287]
and of 10 different fatty acids (excluding EPA and DHA)
tested for their bioactivites on PPAR-gamma, ALA was
determined to be the most potent activator [288].Lipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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The inhibitory effects of EPA and DHA on NF-kB have
recently been reviewed [289]. EPA and DHA administra-
tion in fish oil has also reduced mRNA levels of inflamma-
tory mediators including TNF-alpha, IL-1B, and IL-6 in
various animal studies [290-292], confirming a mechanis-
tic link between inflammation, EPA+DHA, and gene
expression. A connection has also been identified
between EPA and DHA and the function, distribution,
and activation of PPARs, given their antagonistic effect on
LTB4 production and action [293]. This suggests an influ-
ential role of n-3 PUFA on PPARs, which has been sup-
ported by others [294]. EPA and DHA have also been
shown to be more potent in vivo activators of PPARα than
other fatty acids [295], suggesting a preferential role of
these fatty acids in PPAR pathways.
Limitations and considerations
While research on n-3 PUFA has produced exciting results,
it is not without inconsistencies and there are several fac-
tors that currently limit the utility of some study out-
comes. For example, food frequency questionnaires, often
used in nutritional epidemiology as a method of assessing
dietary intake, may produce inaccurate results. Question-
naires are subject to recall bias and the food composition
databases they are based upon may lack precision in
quantifying actual nutrient intake. Alternatively, erythro-
cytes have been used as biomarkers for dietary intake of
fatty acids, however, they too lack complete accuracy.
Some sources indicate erythrocyte membrane fatty acid
composition is reflective of typical diet at approximately 4
months [296], whereas other research suggests RBC mem-
brane levels of fatty acids reflect dietary intake after only 3
weeks [96,297]. Further, fatty acid levels in the blood do
not necessarily accurately predict levels in all tissues, pos-
sibly due to inter-individual differences in fatty acid
metabolism [298]. Identification of tissue-specific
biomarkers for fatty acid intake would be of high utility.
The relationship between ALA and chronic disease is
unclear. In terms of research on insulin resistance, cell cul-
ture work is lacking, however animal studies tend to sup-
port a beneficial role of ALA on insulin sensitivity. On the
other hand, human outcomes demonstrate a greater
degree of variability. This could be explained, in part, by
the fact that supplementation study results can be con-
founded by background intake of fish, walnuts, flaxseed,
or other n-3 PUFA-rich foods in humans [177,186].
Similarly, research on ALA and prostate cancer in rodents
fails to demonstrate any significant association, while
human dietary questionnaire-based studies suggest a
trend towards a tumour-promoting role of ALA. Interest-
ingly, blood and tissue analyses in this area produce a
wide range of results, from positive associations between
tissue ALA and prostate cancer to negligible or negative
associations between ALA levels in the blood and prostate
cancer risk. In contrast, the literature surrounding breast
cancer and ALA is more consistent and suggests an anti-
tumourigenic effect of this fatty acid in rodents and
humans. Several factors could be contributing to such var-
iability in study results, including tissue-dependent differ-
ences in tumorigenesis, diverse modes of ALA
supplementation and measurement, and variability in
study length, subject characteristics and outcome meas-
ures. Further, ALA-rich flaxseed, which is often used in
human supplementation studies, has varying degrees of
bioavailability depending on whether it is administered in
its whole, ground, or oil form [299].
The robust cardioprotective effects of n-3 PUFA from
marine sources are well documented, however a general
consensus on the beneficial relationship between ALA
and CVD is still lacking. Part of the problem stems from
the fact that chronic diseases like CVD take many years to
develop and are often defined by the co-existence of mul-
tiple risk factors. Further, each risk factor could be differ-
entially impacted by ALA and other dietary fatty acids
making it difficult to determine the precise mechanisms
and complex interrelationships involved. This could help
account for some of the discrepancy in the literature sur-
rounding ALA and CVD. The results of several recent
human studies, however, are intriguing and warrant fur-
ther investigation.
Future directions and conclusion
Research has assessed the effects of n-3 PUFA in diverse
models of disease with different study designs and varying
outcome measurements. While this is a valuable contribu-
tion to the breadth of the literature, additional mechanis-
tic and human studies are warranted to further
substantiate previous findings. There is growing recogni-
tion of the potential heterogeneous effects of ALA, EPA
and DHA, which should be considered in future experi-
mental designs.
Clarification of the relationship between n-3 PUFA and
cancer at multiple time points is also needed. Typically,
cancer studies are conducted in older individuals who
have already naturally accumulated considerable DNA
damage, or who have existing tumours or malignancies.
The potential preventative contribution of ALA, EPA and
DHA during mammary or prostate gland development,
however, has yet to be detailed. This could help identify
fatty acid effects at critical developmental time points that
could modify future breast and prostate health.
It is also necessary to clarify how the mode of n-3 PUFA
administration affects physiological outcomes. N-3 PUFA
can be obtained from either dietary sources or via supple-
mentation, and inherent challenges exist with bothLipids in Health and Disease 2009, 8:33 http://www.lipidworld.com/content/8/1/33
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options when attempting to determine resultant n-3
PUFA-specific effects. To further advance the field of PUFA
research, it would be useful for future studies to tease out
the effects of dietary n-3 PUFA from the matrix of food,
which has additional biologically active components.
The health-related effects of EPA and DHA have under-
gone considerable study, however the specific biological
effects of ALA are largely unknown. Therefore, more work
is required to identify the differential effects of ALA on
cancer, insulin resistance and cardiovascular disease. The
need is evermore apparent, given that ALA is by far the
predominant form of n-3 PUFA consumed in the typical
North American diet and its conversion to EPA and DHA
is minimal. Identification of potentially beneficial or det-
rimental effects of ALA intake thus may have a profound
and widespread impact on health promotion or disease
burden.
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